2018 is coming to a close, and somehow, I have managed to make it through a year as the physician editor of The Rheumatologist without being sued or fired, so I thought this would be a good time to pause and reflect on lessons learned—and to give thanks. My first lesson: this is a lot of…
A typical patient with a rheumatic disease needs a multifaceted treatment approach to address comorbidities, minimize disability, promote quality of life and improve survival. To achieve these outcomes, rheumatology research has evolved from examining a single treatment to studying the best treatment approaches. Examples of these strategy trials include how to best combine pharmaceutical therapies,…
Data from multiple clinical trials and an extension study showed baricitinib is safe and effective for the long-term treatment of adults with RA…
The evaluation of a child with arthralgia who has a normal physical examination provides a challenge to rheumatologists. Here are some insights into assessing and treating children with musculoskeletal pain syndromes…
Hydroxychloroquine is not currently used to treat patients with antiphospholipid syndrome (APS). But new research in APS-induced mice shows hydroxychloroquine may improve endothelium-dependent dilation and reduce reactive oxygen species generation…
In 2018, did you interact with the Medicare payment system, receive payment for a consultation code or worry about the Centers for Medicaid & Medicare Services (CMS) reducing reimbursement through its proposal to combine evaluation and management codes in the Physician Fee Schedule? If your answer to any of those questions is yes, then you…
As of Jan. 1, 2019, the Centers for Medicare & Medicaid Services (CMS) will implement several coding and documentation policies to provide immediate burden reduction to providers. The 2019 Medicare Physician Fee Schedule Final Rule (MPFS) released Nov. 1, 2018, by the CMS contained significant changes to the Medicare Part B coding and documentation policies…
WASHINGTON (Reuters)—Four Democratic U.S. senators introduced a bill on Thursday that would allow the government to block drug price increases that it decides are unjustified. The bill sponsored by Senators Richard Blumenthal, Kamala Harris, Amy Klobuchar and Jeff Merkley, all Democrats, would allow the Department of Health and Human Services to prohibit drug price increases…
Big data can benefit rheumatology research. But according to experts at the 2018 ACR/ARHP Annual Meeting, the data must first be accessible, interoperable and shareable…
At the AMA’s recent House of Delegates Interim Meeting, the ACR’s delegation was able to incorporate rheumatology concerns into official AMA policy, in addition to leading a major multi-specialty resolution on the CMS-proposed move to consolidate and cut evaluation and management (E/M) services. The ACR is able to make this progress because members of the…